Stoke Therapeutics

stoke therapeutics is addressing the underlying cause of severe diseases by upregulating protein expression with rna-based medicines. we develop antisense oligonucleotide medicines that increase gene expression to treat genetic epilepsies and other severe monogenic diseases, including genetic conditions affecting the central nervous system, eye, liver and kidney. at stoke, we believe our proprietary technology platform, targeted augmentation of nuclear gene output, or #tango, will allow us to deliver disease-modifying therapies in a highly precise, durable and controlled manner. we have identified approximately 2,900 genetic diseases which we believe may be amenable to tango. at stoke, we are united around a common goal: to improve the lives of people living with severe genetic diseases. stoke is located in bedford, ma with offices in cambridge, ma. connect with us at www.stoketherapeutics.com or on twitter @stoketx.